Daily Stock Analysis, RDHL, Redhill Biopharma Ltd, priceseries

RedHill Biopharma Ltd. is a biopharmaceutical company. Primarily, it is focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. Its current pipeline of proprietary products includes: (i) RHB-105-an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104-an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and an ongoing proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA (RHB-102)-a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106-an encapsulated bowel preparation licensed to Salix Pharmaceuticals Ltd.; (v) YELIVA (ABC294640)-a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON-a Phase II-stage first-in-class uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumors; (vii) RP101 is a Phase II-stage first-in-class Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (viii) RIZAPORT (RHB-103)-an oral thin film formulation of rizatriptan for acute migraines and with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

RedHill Biopharma Ltd., an Israeli biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The company's pipeline of therapeutic candidates include RHB-105 intended for the eradication of Helicobacter pylori infection that is under Phase III study; RHB-104 for the treatment of Crohn's disease, which is under Phase III study; BEKINDA for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and gastroenteritis and gastritis that is under phase III study; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract. Its pipeline of therapeutic candidates also comprise MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers that has completed Phase II-stage; RP101, a Hsp27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. The company was founded in 2009 and is based in Tel Aviv, Israel.